BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.

Rhea-AI Summary

BioCorRx Inc. (OTCQB: BICX) announced a potential spin-off of its clinical stage subsidiary, BioCorRx Pharmaceuticals, into a separate publicly traded company. The board believes this move could maximize shareholder value by allowing distinct evaluations of both entities. Lourdes Felix, CEO, highlighted the recent advancements in their product, BICX104, an implantable naltrexone pellet targeting opioid use disorder. The spin-off aims to qualify as a tax-free event for shareholders, although no completion timeline is set, and various conditions must be satisfied.

Positive

• Potential spin-off could maximize shareholder value.
• Distinct evaluation of BioCorRx and BioCorRx Pharmaceuticals.
• Recent progress with BICX104 development aimed at opioid use disorder.

Negative

• No assurance the proposed spin-off will occur.
• Completion subject to various conditions without a set timetable.

ANAHEIM, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a potential spin-off of BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage drug development company, into a separate publicly traded company on a major exchange.

BioCorRx believes that a spin-off will maximize shareholder value by enabling investors to evaluate the performance and future potential of each entity, simplifying capital structures and creating additional long-term company value. If completed, upon effectiveness of the transaction, BioCorRx shareholders would own shares of both companies. Any potential spin-off would be intended to qualify as a tax-free event for U.S. federal income tax purposes to BioCorRx Inc. and its shareholders.

Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “We are exploring a potential spin-off transaction of BioCorRx Pharmaceuticals, as we believe that, if completed, such a transaction would allow us to better align resources, while enabling shareholders to participate in the upside potential. Notably, BioCorRx Pharmaceuticals Inc. has made tremendous progress over the past three years advancing BICX104, an implantable naltrexone pellet for the treatment of opioid use disorder (OUD), via a 505(b)(2) FDA approval pathway. We look forward to rapidly advancing our clinical activities towards commercialization of BICX104, as well as expanding our development pipeline.  We remain focused on saving lives and committed to helping all afflicted by addictive disorders.” 

There can be no assurance that the proposed transaction will be completed in the manner described above, or at all. The Company has not set a timetable for completion of this process. Completion of any spin-off would be subject to various conditions.

About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
212- 671-1020 x304
bicx@crescendo-ir.com

Media Contact
PhillComm Global
BioCorRx@PhillComm.Global
704-942-1557

FAQ

What is the potential spin-off of BioCorRx Pharmaceuticals?

BioCorRx is exploring a spin-off of its clinical stage subsidiary, BioCorRx Pharmaceuticals, into a separate publicly traded company, aiming to enhance shareholder value.

How could the spin-off benefit shareholders of BioCorRx Inc.?

The spin-off is intended to allow shareholders to evaluate the performance of both companies separately, potentially increasing overall value.

What is the current status of BICX104?

BICX104, an implantable naltrexone pellet for opioid use disorder, is progressing through the FDA approval process via a 505(b)(2) pathway.

Is there a timeline for the proposed spin-off transaction?

No specific timeline has been set for the completion of the spin-off, and it is subject to various conditions.